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Introduction
Survival rates from early breast cancer have improved substantially over the past 20 years. However, the incidence of breast cancer has increased and continues to represent a major health problem worldwide. 1 Both the Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview analyses, 2,3 and individual trial data have shown benefi t for adjuvant anthracycline [4] [5] [6] and taxane-containing chemotherapy. [7] [8] [9] Although considerable progress has been made in early breast cancer through large adjuvant randomised treatment trials, these advances have been relatively slow. Follow-up is prolonged in order to meet the prespecifi ed event rate criteria for disease-free survival and overall survival analyses, as defi ned in the statistical analysis plans. 10 Neoadjuvant trials in breast cancer have become increasingly common over the past 10 years, and the primary endpoint of pathological complete response can be reported more rapidly than in their adjuvant counterparts.
Neo-tAnGo was our previous randomised phase 3 neoadjuvant trial and looked at the addition of gemcitabine to an anthracycline-based chemotherapy followed by taxane sequential combination, 11 and also the effi cacy of giving paclitaxel fi rst in the treatment sequence. Although the addition of gemcitabine did not prove eff ective, giving paclitaxel fi rst in the treatment sequence resulted in greater proportions of patients achieving a pathological complete response. Therefore, in the ARTemis trial reported here we used a taxane fi rst in the treatment sequence. At the time of development of the ARTemis trial in 2008, there was considerable interest in the role of bevacizumab in breast cancer because phase 3 trials had reported benefi t in the metastatic setting. 12, 13 Other neoadjuvant breast cancer trials testing the effi cacy of bevacizumab (NSABP B-40 and GeparQuinto) had been announced. We developed the ARTemis randomised trial to test the hypothesis that the combination of bevacizumab with neoadjuvant anthracycline and taxane-based chemotherapy might improve the proportion of patients achieving a pathological complete response in breast cancer with acceptable toxicity. This study presents the results of the primary endpoint analysis.
Methods

Study design and participants
The ARTemis phase 3 randomised trial aimed to assess the benefi t of the addition of neoadjuvant bevacizumab to chemotherapy in terms of short-term and long-term outcomes in women presenting with early breast cancer. We enrolled women aged 18 years or older with a histological diagnosis of early invasive breast cancer, and a radiological tumour size of more than 20 mm with or without axillary involvement. Patients were enrolled at 66 National Cancer Research Network sites in the UK. Patients with infl ammatory cancer, T4 tumours with direct extension to the chest wall or skin, and ipsilateral supraclavicular lymph node involvement were eligible with any size of primary tumour. We regarded hormone oestrogen receptor (ER) status as negative when Allred score was 0-2/8; ER weakly positive was 3-5/8; and ER strongly positive was 6-8/8. These ER categories were based on those already used by our group in the tAnGo trial 14 and subsequently confi rmed by Petit and colleagues 15 to be predictive of neoadjuvant chemotherapy response (pathological complete response) in ER-positive tumours. All patients were HER2 negative, defi ned as immunohistochemistry of 0/1+, or if 2+, fl uorescence insitu hybridisation showed no evidence of amplifi cation of the HER2 gene. Other eligibility criteria were adequate cardiac function (left ventricular ejection fraction within the normal institutional range, as assessed by multiplegated acquisition scan or echocardiogram), adequate bone marrow, hepatic, and renal function, and appropriate Eastern Cooperative Oncology Group (ECOG) performance status (0-2). In view of potential side-eff ects from bevacizumab, patients had to have no previous diagnosis of ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, arterial or venous thromboembolic disease, cardiac failure, gastroduodenal
Research in context
Evidence before this study When the ARTemis trial was developed, survival from early breast cancer had improved over the preceding 20 years, in part through large randomised adjuvant treatment trials. Individual trials and the Early Breast Cancer Trialists Collaborative Group overviews had shown benefi t for taxane and anthracycline chemotherapy, but intensifi cation had failed to yield further rapid progress. Neoadjuvant trials in breast cancer have been increasingly pursued with the early primary endpoint of pathological complete response as a surrogate for activity and improvement in long-term outcomes. In 2008 there was great interest in the role of the anti-angiogenic monoclonal antibody bevacizumab because phase 3 trials of bevacizumab had reported benefi t in the metastatic setting. Other neoadjuvant trials of bevacizumab in HER2-negative breast cancer were in progress or development including GeparQuinto, CALGB 40603, and NSABP B-40. We developed the ARTemis UK multicentre trial to test the hypothesis that the combination of bevacizumab with neoadjuvant taxane and anthracycline containing chemotherapy might improve the proportion of patients achieving a pathological complete response in HER2-negative breast cancer, with acceptable toxicity. The ARTemis trial also collected tumour and blood from participants for future translational studies seeking molecular characteristics predicting benefi t from bevacizumab, a key to optimising costeff ectiveness in future.
Added value of this study
This report presents the primary endpoint of pathological complete response in ARTemis, showing a signifi cant improvement in the proportion of patients achieving a pathological complete response with the addition of bevacizumab to neoadjuvant chemotherapy. Pathological complete response in oestrogen receptor (ER) strongly positive patients was achieved in fewer patients and did not appear to improve with bevacizumab, compared with ER negative and ER weakly positive patients.
Implications of all the available evidence
Our results extend those reported in GeparQuinto and CALGB 40603, but also off er an explanatory hypothesis for the otherwise apparently divergent results of NSABP B-40, in which ER positive patients appeared to benefi t most. We postulate that known variations between the trials in ER status defi nition might have resulted in varying distribution of ER weakly positive patients across the dichotomised ER positive and negative categories, thus explaining the apparently divergent results. We also hypothesise that molecular characteristics of individual tumours, similar to those recently observed in ovarian cancer trials of bevacizumab, might correlate with ER status and underlie the variations in individual patient benefi t observed. Meta-analysis of ARTemis, GeparQuinto, CALGB 40603, and NSABP B-40 with analysis of their linked translational collections could test these hypotheses with suffi cient statistical power in the future. ulcer, symptomatic diverticulitis, or infl ammatory bowel disease. Additionally, no uncon trolled hypertension, defi ned by a systolic pressure greater than 150 mm Hg or diastolic pressure greater than 90 mm Hg, with or without antihypertensive medication was allowed. Patients with initial increases in blood pressure were eligible if initiation or adjustment of antihypertensive medication lowered pressure to meet entry criteria.
No previous exposure to chemotherapy, radiotherapy, or endocrine therapy as treatment for breast cancer was allowed. Full eligibility criteria can be found in the trial protocol.
ARTemis was an investigator designed and led trial, granted a Clinical Trials Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on Feb 25, 2009 , approved by the Multi-Centre Research Ethics Committee nationally on March 26, 2009 , and subsequently by the local research ethics committees at all participating centres. All patients provided written informed consent.
Randomisation and masking
We randomly assigned participants (1:1) to two chemotherapy regimens using a central computerised minimisation procedure. Treatment allocations were made by telephone to the Warwick Clinical Trials Unit, where a central computerised minimisation procedure was used to generate the patients' random allocation. Stratifi cation by minimisation was done by age (≤50 years vs >50 years), ER status (negative vs weakly positive vs strongly positive), total tumour size (≤5 cm vs >5 cm), clinical involvement of axillary lymph nodes (yes vs no), and disease type (infl ammatory or locally advanced or both vs neither). Randomisation was recommended within 4 weeks of the initial core biopsy and chemotherapy to start within 1 week of randomisation. The trial was open label.
Procedures
Chemotherapy regimens used were docetaxel 100 mg/m² once every 21 days for three cycles, followed by fl uorouracil 500 mg/m², epirubicin 100 mg/m², with cyclophosphamide 500 mg/m² once every 21 days for three cycles (D-FEC). Bevacizumab 15 mg/kg (Genentech, South San Francisco and Vacaville, CA, USA) was given every 3 weeks with the fi rst four cycles of chemotherapy in the experimental group (Bev+D-FEC).
We assessed adverse events for each chemotherapy cycle by grade according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. We also recorded use of growth factor support (either granulocyte colony stimulating factor [GCSF] or pegylated [PEG] GCSF). The maximum permitted dose delay or interruption was 4 weeks to allow recovery from severe toxicity or for unscheduled procedures (eg, emergency surgery). If neutropenic fever or sepsis occurred after a cycle of chemotherapy, the next cycle was delayed until the absolute neutrophil count was at least 1·0 × 10⁹ cells per L. After a delay, either dose reduction of all drugs to 80%, or GCSF support with 100% dose were allowed, and all remaining cycles of the same three-cycle block were given at those doses. For persistent thrombocytopenia, the next cycle was delayed until platelets had recovered to at least 100 × 10⁹ cells per L and chemotherapy doses were reduced to 80%, maintaining this dose reduction for subsequent cycles. Cycles from the next block of treatment were commenced at full protocol dose, and permitted delays and reductions were made as necessary. Primary prophylaxis with GCSF was allowed with docetaxel with or without bevacizumab, but not with FEC with or without bevacizumab. However, once started, prophylactic GCSF was usually continued into the second phase of chemotherapy at the discretion of the responsible physician.
If grade 2 neuropathy occurred during treatment with docetaxel, remaining doses were reduced to 75 mg/m². If grade 3 neuropathy occurred, docetaxel was stopped. If fewer than three cycles of docetaxel had been given, additional FEC cycles were allowed up to a maximum of six cycles in total, at the discretion of the treating consultant.
Cardiac toxicity was checked by left ventricular ejection fraction before treatment started and after four cycles of chemotherapy with or without bevacizumab. If congestive cardiac failure developed, patients were investigated and 1 did not undergo surgery 1 protocol violator refused surgery 1 did not have lymph node examination after chemotherapy 6 withdrew consent for further follow-up before surgery 6 were ineligible 4 with tumours 20 mm or less 1 with a second breast tumour that was HER2-positive 1 with liver metastases 8 had baseline blood pressure measurements outside of the protocol stated limits 399 assigned to Bev+D-FEC 388 included in the primary endpoint analysis 4 did not undergo surgery 3 withdrew from the trial due to early disease progression or inadequate response to chemotherapy 1 had inflammatory disease after neoadjuvant chemotherapy 7 withdrew consent for further follow-up before surgery 1 ineligible because of bone metastases 6 had baseline blood pressure measurements outside of the protocol stated limits 800 participants randomly assigned
For the trial protocol see www. warwick.ac.uk/go/artemis treated as appropriate, bevacizumab and epirubicin were discontinued, and other chemotherapy was given at the discretion of the treating clinician.
In the event of an allergic reaction to docetaxel, the infusion was stopped if mild symptoms of skin rash, fl ushing, and localised pruritus occurred. Intravenous steroids and antihistamines were given and immediate slow rechallenge of chemotherapy was used on recovery. Docetaxel infusion was stopped if moderate symptoms of generalised pruritus or rash, mild dyspnoea, or mild hypotension occurred, and intravenous steroids and antihistamines were given. Steroids were then advised for 48 h before cautious docetaxel rechallenge. If severe allergic symptoms occurred, including bronchospasm, generalised urticaria, angio-oedema, hypotension (systolic blood pressure <100 mm Hg), or life-threatening anaphylaxis, docetaxel infusion was stopped and treatment was given with intramuscular epinephrine (1 mL, 1:1000), intravenous steroids, and intravenous antihistamines; rechallenge was contraindicated.
Surgery (breast and axillary), radiotherapy, and adjuvant endocrine treatment were done according to local protocols. Clinical surveillance will continue for 5 years at the clinical centres, and after 5 years with the Offi ce for National Statistics. Patients will continue to receive follow-up through the National Cancer Intelligence Network (NCIN) with monitoring of disease-free survival and overall survival.
The reporting of pathological complete response and minimal residual disease was by an independent, central, two-reader masked review of all anonymised local surgical histopathology reports undertaken by the cochief investigators (HME and LHa). When designing the trial, the primary endpoint pathological complete response was based on local report review and this is consistent with the study protocol. This manuscript adheres to our protocol and provides a measure comparable to other recent and similar trials (GeparQuinto, NSABP B-40, and CALGB 40603). When agreement was not reached, further review by the two study histopathologists (JT and EP) was done. In each case, a consensus on pathological complete response, and pathological complete response or minimal residual disease in the breast alone was agreed. Additionally, a detailed anonymised and masked central pathological review of all biopsies and surgical haematoxylin and eosin slides for pathological complete response is in progress. A quality assurance comparison (using a κ statistic) has been done in cases reviewed to date, between central pathological review of the haematoxylin and eosin slides (all cases done by JT) and the local histopathology reports for the primary endpoint of pathological complete response.
Outcomes
Our primary endpoint was pathological complete response, defi ned as absence of invasive breast cancer in the breast and axillary lymph nodes, after neoadjuvant chemotherapy. Residual non-invasive ductal carcinoma in situ was allowed. Secondary endpoints included pathological complete response or minimal residual disease in the breast alone, which was defi ned as 10% or less of original tumour burden remaining at surgery, and has previously been reported as a potentially useful secondary endpoint in neoadjuvant studies. 16 Other protocol-defi ned secondary endpoints-that are not reported here-include disease-free survival and overall survival. These will be analysed in early 2016 when it is anticipated that median follow-up will be at least 36 months or 120 disease-free survival events will have occurred.
Statistical analysis
The power calculations assume a 70 to 30 split in the trial sample between ER-positive and ER-negative tumours, respectively. The proportion of patients achieving a pathological complete response with the standard treatment (D-FEC) was estimated as about 10% for ERpositive tumours and 25% for ER-negative tumours. On this basis, a trial randomly assigning 400 patients into each of the two treatment groups would allow an absolute diff erence in the proportion of patients achieving a pathological complete response in excess of 10% to be detected at the 5% (two-sided) level of signifi cance with an 85% power. A 10% diff erence in the proportion of patients who achieve a pathological complete response is the most widely accepted in neoadjuvant chemotherapy trials and was used in this group's previously reported Neo-tAnGo trial. 11 The proportion of patients achieving pathological complete response was calculated for all patients known to have had surgery. The χ² test with continuity corrections was used to compare treatment groups. Multivariate logistic regression provided p values for the treatment eff ect after adjustment for stratifi cation factors.
As a secondary analysis, the proportion of patients achieving pathological complete response in the breast alone was assessed along with those achieving pathological complete response or minimal residual disease, and comparisons across treatment groups were made using multivariate logistic regression with adjustment for prognostic factors.
The sample size of our study is too small to permit multiple subgroup analyses, and so we chose not to do tests for statistical signifi cance in each ER subgroup separately.
The methods for dose intensity calculations have been described previously. 17 Chemotherapy course delivered dose intensities were compared across treatment groups using Wilcoxon rank-sum tests and Fisher's exact tests.
Common Toxicity Criteria (CTC) grades were recorded for each chemotherapy cycle and growth factor support (usually GCSF) was also recorded. The reports of grade 3 and 4 toxicities were examined in detail.
Statistical analysis was done on an intention-to-treat basis and therefore all patients who were ineligible, or whose treatment violated the trial protocol, were analysed within their randomised treatment groups. All reported p values are two-sided. Analysis was undertaken by Warwick Clinical Trials Unit, using SAS statistical 
Role of the funding source
The funders of the study (Cancer Research UK, Roche, and Sanofi -Aventis) had no role in study design, data collection, data analysis, data interpretation, or writing of the report. HME, LHi, and LHa had full access to all of the data and had fi nal responsibility for the decision to submit for publication with the agreement of all the authors and the data monitoring and safety committee.
Results
800 patients were recruited at 66 UK centres (between May 7, 2009, and Jan 9, 2013) and randomly assigned to either D-FEC (401 patients) or Bev+D-FEC regimens (399 patients; fi gure 1). Patient and tumour characteristics were balanced across treatment groups (table 1) . We subsequently identifi ed seven patients as ineligible; six in the D-FEC group (four with tumours 20 mm or less, one with a second breast tumour that was HER2-positive, and one with liver metastases); and one in the Bev+D-FEC group (with bone metastases). Additionally, 14 patients (eight in the D-FEC group and six in the Bev+D-FEC group) had baseline blood pressure measurements outside of the protocol stated limits. All patients were included in analyses on an intention-to-treat basis. 782 patients had post-chemotherapy pathology reports from surgery available for review, 781 of which could be used for assessment of the primary endpoint of absence of invasive breast cancer in the breast and axillary lymph nodes. 153 (20%) of all 781 patients achieved a pathological complete response: 66 (17%, 95% CI 13-21) in the D-FEC group and 87 (22%, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] in the Bev+D-FEC group (diff erence 6%, 0·1-11·2; p=0·03 after adjustment for stratifi cation factors, p=0·06 for the unadjusted analysis; table 2 and fi gure 2). The proportion of patients overall who achieved a pathological complete response diff ered signifi cantly across both ER status (ER negative 38% [95% CI [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , weakly positive 41% , strongly positive 7% [5] [6] [7] [8] [9] ; p<0·0001), and tumour grade (grade 1/2 7% [4] [5] [6] [7] [8] [9] [10] [11] , grade 3 29% [25-34]; p<0·0001). ER negative, ER weakly positive, and grade 3 patients appeared to benefi t from the addition of bevacizumab whereas ER strongly positive and grade 1/2 patients did not appear to benefi t from the addition of bevacizumab (table 2 ). An analysis of benefi t for bevacizumab for each level of Allred score (ER status), confi rmed that our categories of ER weakly positive (Allred 3-5/8) and ER strongly positive (Allred 6-8/8) were the correct cut points both for pathological complete response rate and benefi t for bevacizumab (appendix). Complete central pathology specimen review for the trial is in progress and will be reported later. Preliminary results show very good agreement between central pathology review and local pathology report review for pathological complete response in the breast and axilla (agreement in 95% of cases, κ 0·83 [95% CI 0·76-0·90]).
The proportion of patients achieving a pathological complete response in the breast alone was signifi cantly higher in the Bev+D-FEC group than in the D-FEC group (diff erence 6% [95% CI 0·1-12·1]; p=0·02 after adjustment for stratifi cation factors; Favours D-FEC Favours Bev+D-FEC
OR (95% CI)
See Online for appendix
Number of patients
Allergic reaction to docetaxel; switched to FEC early 11
Wound complications or infection 10 The individual cycle dose intensities both for chemotherapy and bevacizumab did not show substantial attrition over time (appendix). There were also no substantial diff erences between the docetaxel and the FEC blocks of chemotherapy (data not shown). Of the 386 (9%) reports of chemotherapy dose reductions from 4418 chemotherapy cycles, dose reductions were most commonly reported in cycles 2 and 3 and again in cycles 5 and 6, in both treatment groups (table 4). A slight increase in reports of treatment delays was also noted in cycles 2, 5, and 6 across both treatment groups (table 4) . Reports of modifi cations to bevacizumab administration were infrequent throughout the four cycles (table 5) .
GCSF was used in 2744 (62%) of 4418 cycles with slightly higher rates in the Bev+D-FEC group in all treatment cycles (appendix 
Discussion
In the ARTemis study, the addition of short course bevacizumab to standard neoadjuvant anthracycline and taxane-based chemotherapy in HER2-negative, early breast cancer, was associated with a signifi cant improvement in the proportion of patients achieving a pathological complete response. A greater proportion of ER-negative (Allred 0-2) and ER weakly positive (Allred 3-5) patients achieved pathological complete response compared with the ER strongly positive (Allred 6-8) patients. Additionally, bevacizumab combined with chemotherapy appeared to provide more signifi cant benefi t to ER-negative and ER weakly positive patients than to other types. The benefi t of bevacizumab for ER-negative and weakly positive patients is in marked contrast to the ER strongly positive group in which low proportions of patients achieved pathological complete response and there was also an apparent lack of benefi t from bevacizumab. The ARTemis treatment protocol was deliverable for both chemotherapy and bevacizumab, and toxicity from chemotherapy was as expected for D-FEC, although there was an increase in grade 4 neutropenia in patients given Bev+D-FEC, as reported previously. 18 The observed diff erences in pathological complete response were statistically signifi cant in the group as a whole. However, the clinical signifi cance of the addition of bevacizumab appears to be most compelling within the ER-negative subgroup. Three other randomised studies have reported on the addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative breast cancer [19] [20] [21] [22] (appendix). Pathological complete response was the primary endpoint in all four studies, albeit with diff ering defi nitions. In GeparQuinto, pathological complete response was defi ned as lack of invasive or in situ cancer in both breast and axilla (ypT0 ypN0). Using this stringent defi nition, bevacizumab signifi cantly increased the proportion of patients achieving pathological complete response in the bevacizumab-containing group compared with the chemotherapy alone group (18·4% vs 14·9%; p=0·04) in the overall study population. 19 Bevacizumab signifi cantly increased the proportion of patients achieving a pathological complete response in the 633 patients with triple-negative disease (27·9% increased to 39·3%, p=0·003) but not in the 1262 patients with hormonereceptor-positive tumours (7·7% increased to 7·8%, p=1·0). The GeparQuinto results are supported by those of CALGB 40603, which enrolled triple-negative patients only. 20 In this smaller study, the addition of bevacizumab signifi cantly increased the proportion of patients achieving a pathological complete response (defi ned as absence of invasive disease in breast only [ypT0/Tis]) in the bevacizumab group compared with the chemotherapy alone group (59% vs 48%; p=0·009). The results of these two studies are very similar to our study, in which a greater proportion of patients treated with bevacizumab achieved a pathological complete response (defi ned as no invasive disease in breast or axilla [ypT0/Tis ypN0]) than those treated with chemotherapy alone (22% vs 17% in the overall study population and 44% vs 32% in ER/ HER2-negative patients). Contrary to these three studies, in NSABP B-40, the addition of bevacizumab increased the proportion of patients achieving a pathological complete response (defi ned as ypT0/Tis) in hormonereceptor-positive breast cancers when compared with the chemotherapy alone group (23·2% vs 15·1%, p=0·007) but not in triple-negative patients (51·5% vs 47·1%, p=0·34). 21 Several points can be made if one is to try to reconcile the diff erences in outcomes between these four studies. First, since the tests for interaction between hormone receptor status and treatment group were nonsignifi cant in both NSABP B-40 and GeparQuinto, a statistical diff erential eff ect of bevacizumab according to hormone receptor has not yet been proven. Second, all four studies used diff erent chemotherapy backbones and both NSABP B-40 and CALGB 40603 had factorial designs where modifi cations of the chemotherapy regimens were tested in parallel with the addition of bevacizumab, rendering cross-trial comparisons even more diffi cult. As an example, in CALGB 40603, the proportion of patients who received both carboplatin and bevacizumab with standard chemotherapy and achieved a pathological complete response (defi ned as ypT0/Tis ypN0) was numerically highest (60%), compared with patients who received either carboplatin and standard chemotherapy (49%), bevacizumab and standard chemotherapy (43%), or standard chemotherapy alone (39%). 20 Third, in GeparQuinto, patients with no clinical response after the fi rst anthracycline-based component of the study were removed from the study, potentially introducing bias that is diffi cult to quantify. 19 Fourth, whereas hormonereceptor-positive patients were defi ned as those showing more than 10% positive cells for either ER or progesterone receptor in GeparQuinto and CALGB 40603, the NSABP B-40 trial used a 1% cutoff . We used an Allred score greater than 2 to identify ER-positive patients, a defi nition very close to that of NSABP B-40. In our trial, ER weakly positive patients (although a small stratifi ed subgroup; n=75) showed similar chemotherapy response and benefi t from bevacizumab to the ER-negative group. Therefore, it is possible that the increased proportion of patients who achieved a pathological complete response in ER-positive patients in NSABP B-40 is driven by patients with low ER scores who were excluded from GeparQuinto and CALGB 40603.
A point of convergence can be found if pathological complete response is defi ned as we have in our study (ie, absence of invasive disease in breast and axilla but allowing residual ductal carcinoma in situ in the breast [ypT0/Tis ypN0]). This is reported as the primary outcome in our study and as a secondary endpoint in the other three studies. Using this defi nition, pathological complete response is not signifi cantly higher with the addition of bevacizumab in the overall study population in any of the three previously reported studies. [19] [20] [21] However, pathological complete response is still signifi cantly improved in triple-negative patients in GeparQuinto 23 and in hormone-receptor-positive patients in NSABP B-40. We believe that a meta-analysis of all four studies with uniform defi nitions of hormone receptor and pathological complete response is needed to identify a subgroup of patients in whom bevacizumab increases pathological complete response. With that in mind, and acknowledging that the sample size of our study is too small for subgroup analyses, we chose not to do tests for statistical signifi cance in each ER subgroup separately (table 2) .
The use of pathological complete response as a trial endpoint is to some extent dependent on its role as a surrogate for meaningful clinical outcomes such as disease-free survival, distant relapse-free interval, breast cancer specifi c survival, and overall survival. Some of these have very recently been reported for the GeparQuinto study 24 and show no diff erence for the addition of bevacizumab at 3 years for either disease-free survival (HR 1·03, 95% CI 0·84-1·25) or overall survival (0·97, 0·75-1·26). Results might be confounded because no bevacizumab was given after surgery and patients who were not responding on ultrasound assessment, at the midpoint of their neoadjuvant treatment, were off ered randomisation into a novel treatment group with everolimus. Another explanation is that since bevacizumab is a targeted anti-angiogenic agent, it is potentially less likely to eradicate micrometastatic disease in the bone marrow. We hypothesise that there is unlikely to be synergism between chemotherapy and bevacizumab in the bone marrow because this disease is not dependent on angiogenesis for its survival. Whereas an increased incidence of pathological complete response occurs in the well-developed primary tumour, which is angiogenesis-dependent, there might be no such advantage in terms of increased eradication of eventually lethal distant micrometastatic bone marrow disease. An indication that this mechanism might be operating is provided by the observation that patients who achieved pathological complete response in the bevacizumab group in the GeparQuinto trial had double the risk of relapse of those in the chemotherapy-only group (HR 2·02, 95% CI 0·965-4·22). 24 Additionally, precisely because bevacizumab is an anti-angiogenic agent, once the treatment course is completed, there might be a rebound of tumour cell growth, as has been reported in advanced ovarian cancer after completion of bevacizumab therapy. 25 Similar mechanisms could explain the lack of benefi t from adjuvant bevacizumab added to standard chemotherapy, reported in both the BEATRICE trial 26 and the ECOG Study E5103. 27 At the 2014 San Antonio Breast Cancer Symposium, the NSABP B-40 group presented disease-free survival, distant recurrence-free interval, and overall survival results 28 with a median follow-up of 4·7 years. These results were surprisingly diff erent from those of the recently published GeparQuinto, and showed benefi t for bevacizumab given in the neoadjuvant setting followed by adjuvant treatment. For ER-positive patients the HRs for disease-free survival, distant recurrence-free interval, and overall survival were 0·73 (95% CI 0·53-1·00; p=0·05), 0·68 (0·47-0·97; p=0·03), and 0·63 (0·42-0·96; p=0·03), respectively. The inclusion of adjuvant bevacizumab in the NSABP B-40 study is the major diff erence between these four neoadjuvant bevacizumab studies and might be an important factor in explaining the benefi t of bevacizumab on longer term outcomes in this trial, although this was not confi rmed in the adjuvant studies. 26, 27 Another explanation is that with a median follow-up of 4·7 years, it is too early to draw conclusions about overall survival and distant recurrence-free interval in the ER-positive group in this trial. 10 The relation between the primary endpoint of pathological complete response in therapeutic neoadjuvant trials and longer term outcomes is complex. Hatzis and colleagues 29 have explored this in depth, and have modelled data from neoadjuvant trials and made two conclusions. First, that in high-risk breast cancer the design of neoadjuvant trials could increase the numbers of patients to a level that would make a positive correlation between the primary endpoint (proportion of patients achieving pathological complete response) and longer term outcomes more likely. Second, that including lesser degrees of pathological response could improve the correlation between a (thereby newly defi ned) primary endpoint of pathological response. Pathological complete response has been convincingly proven to be a strong positive predictive factor for improved event-free survival and overall survival in individual patients by the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) Consortium. 30 In their analysis, pathological complete response, defi ned as ypT0/Tis ypN0, resulted in improved event-free survival (HR 0·48, 95% CI 0·43-0·54) and overall survival (0·36, 0·31-0·42). This relation, however, breaks down at the trial level. In the CTNeoBC analysis of 12 trials and 11 955 patients, the coeffi cient of determination (R²) was only 0·03 for eventfree survival and 0·24 for overall survival, meaning that only 3% and 24% of the variability in event-free survival and overall survival, respectively, between trial groups can be explained by diff ering proportions of patients achieving a pathological complete response. These results have been corroborated in a further trial-level analysis of 29 trials and 14 641 patients that reported R² values of 0·08 and 0·09 for disease-free survival and overall survival, respectively. 31 In light of this, the Food and Drug Administration accelerated licensing approval for new compounds doing well in neoadjuvant breast cancer studies in early breast cancer subtypes with high risk of recurrence 32 should be treated with caution, and depending on the results from trials of newer targeted agents, might need modifi cation in the future.
Are there potential independent tumour biomarkers of response to bevacizumab available? The recent report at the American Society for Clinical Oncology 2014 annual meeting of an expression signature for angiogenesis in ovarian cancer 33 is an exciting development. This signature might prove to be a poor prognosis biomarker in epithelial ovarian cancer, and might be predictive for benefi t from bevacizumab. Absence of this signature in epithelial ovarian cancer possibly denotes good prognosis disease and paradoxically detrimental eff ect from the addition of bevacizumab to standard chemo therapy. These results need to be tested prospectively in other datasets. The translational ARTemis group plan to explore, using samples from the ARTemis trial biobank, whether the same angiogenic signature in breast cancer could provide a predictive biomarker of response to bevacizumab.
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